title: [Benign prostatic hyperplasia--its treatment with Proscar].
abstract: Benign prostate hyperplasia is a potentially serious condition affecting men in advanced age. The treatment is conservative and operative. Proskar of Msd is one of the drugs yielding encouraging results. It is a synthetic 4-azosteroid compound, and represents a new class of specific inhibitors of 5-alpha reductase, promoting stabilization of testosterone and the more active androgen dihydrotestosterone (DHT). A total of 35 patients undergo treatment with Proskar at 5 mg daily dose (one tablet) over a 6-month period. The study includes six patients with complete urinary retention. The results are assayed by the change in prostate gland volume, residual urine and maximal urinary flow, 6 PsA. Completely responsive to treatment are 71.44 per cent of patients, partial effect is recorded in 22.85 per cent, and no effect whatsoever--in 5.71 per cent.
authors.forename: P
authors.initials: P
authors.lastname: Panchev
authors.forename: K
authors.initials: K
authors.lastname: Neĭkov
authors.forename: P
authors.initials: P
authors.lastname: Simeonov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D042944:Cholestenone 5 alpha-Reductase; D002908:Chronic Disease; D004341:Drug Evaluation; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology; D012074:Remission Induction; D014563:Urodynamics / Q000187:drug effects
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase
vernacular_title: Dobrokachestvana prostatna khiperplaziia--lechenie s proskar.